Treace Medical Concepts (TMCI) Debt to Equity (2020 - 2026)

Treace Medical Concepts has reported Debt to Equity for 7 years, with the latest figure at $0.75 in Q1 2026.

• For the quarter ending Q1 2026, Debt to Equity rose 47.12% year-over-year to $0.75; the trailing twelve-month figure through Mar 2026 stood at $0.75 (up 47.12% YoY), and the FY2025 full-year result was $0.66, up 39.02% from the prior year.
• Debt to Equity for Q1 2026 stood at $0.75, up from $0.66 in the prior quarter.
• The five-year high for Debt to Equity was $0.87 in Q4 2022, with the low at $0.33 in Q1 2023.
• Historically, Debt to Equity has averaged $0.54 across 5 years, with a median of $0.51 in 2025.
• Annual changes were most pronounced in 2022 — Debt to Equity soared 181.03% — and 2023, when it sank 55.87%.
• Treace Medical Concepts' Debt to Equity stood at $0.87 in 2022, then slumped by 55.87% to $0.38 in 2023, then advanced by 22.87% to $0.47 in 2024, then surged by 39.02% to $0.66 in 2025, then rose by 13.67% to $0.75 in 2026.
• The last three Debt to Equity figures came in at $0.75 (Q1 2026), $0.66 (Q4 2025), and $0.62 (Q3 2025), per Business Quant data.